Drug Watch

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Review the latest FDA pediatric dermatology updates, including dupilumab for childhood CSU, secukinumab for teen HS, and new CHE and infant eczema topical filings.

Maria Hordinsky, MD, breaks down phase 3 data that show topical clascoterone boosts male pattern hair growth for 12 months, targeting follicles without systemic hormonal adverse effects.

Aclaris Therapeutics shares promising Phase 1a data for ATI-052, showing long-acting dual Th2 blockade, and advances ATI-2138 toward Phase 2b lichen planus studies.

The application is based on phase 3 UP-AA trial data showing significant hair regrowth in patients with severe alopecia areata.

Interim phase 2a data show ORKA-001, a half-life extended IL-23 inhibitor, achieved complete skin clearance in 63.5% of patients at week 16.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Potential FDA approval of TrenibotE was delayed due to manufacturing-related issues, with no concerns regarding safety, efficacy, or clinical trial data.

Early clinical trials indicate that dual- and triple-target antibodies may provide faster onset and more consistent itch relief in moderate to severe AD.

Medicus seeks FDA orphan drug status for SkinJect, a dissolvable microneedle doxorubicin patch targeting Gorlin-related basal cell carcinomas, aiming to reduce the need for repeated surgery.

The biologic is the first of its kind approved for young children with antihistamine-refractory CSU, expanding an existing indication that previously covered adults and adolescents.

REZPEG shows growing hair regrowth at 52 weeks in severe alopecia areata, with favorable safety, hinting at a new biologic alternative to JAKs.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Phase 3 data show clascoterone solution sustains hair regrowth for 12 months with vehicle-like safety, paving the way for a novel male androgenetic alopecia option.

FDA will review LEO Pharma's delgocitinib cream for adolescent patients aged 12-17 with CHE, backed by phase 3 gains and addressing a major treatment gap.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Phase 2/3 brepocitinib trial will target moderate to severe LPP, aiming to calm inflammation and symptoms and potentially deliver the first FDA-approved systemic option.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Mark Jackson, MD, of Evommune, provides a therapeutic update on the investigational atopic dermatitis drug, citing strong efficacy and safety after just 2 doses, with phase 2b research on the way.

Kimball presented new data on MoonLake Immunotherapeutics’ sonelokimab and reflected on other HS updates presented at AAD 2026.

Hoth Therapeutics has received regulatory approval in Hungary to expand the phase 2 trial into Europe, with Spain and Poland approvals anticipated.

LPP affects roughly 100,000 adults in the US and currently has no FDA-approved treatments.

The combination therapy SHORE trial produced the highest response rates of the 3 studies, with EASI-75 approaching 48% in the Q4W arm.

Phase 3 data presented at AAD 2026 show once-daily oral therapy clears skin as early as week 4, offering a fast-acting option for patients.

Late-breaking data shared at AAD 2026 supports oral TYK2 envudeucitinib's efficacy and safety in moderate-to-severe plaque psoriasis.